Navigation Links
Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
Date:11/23/2009

PRINCETON, N.J., Nov. 23 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that the enrollment of Cohort 2, led by its partner Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY), will continue for the remaining 300 genotype 1 and 4 patients in the ongoing phase 2b trial of RG7128, a first-in-class nucleoside analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. The decision was reached after a scheduled review by an independent Data Monitoring Committee (DMC) of all available safety data from the first cohort of approximately 100 patients completing 8 or 12 weeks of RG7128 or matching placebo in combination with pegylated interferon and ribavirin.

The DMC reviewed any potential drug discontinuations, incidence and details of adverse events, and selected laboratory assessments. No safety events in the DMC review were considered significantly different from those expected from HCV patients taking pegylated interferon and ribavirin treatment. The committee expressed no safety concerns that would preclude enrollment of the remaining 300 patients in the ongoing phase 2b study in the HCV positive genotype 1 and 4 population, and have not recommended modification of dose or duration of any RG7128 dosing regimens. Enrollment of these patients pre-screened for this Cohort in the fourth quarter 2009 has begun and is expected to be complete by the end of the first quarter of 2010.

"We welcome Roche's decision to open enrollment of Cohort 2 for the remaining 300 patients in the phase 2b trial," stated Michelle Berrey, MD, MPH, Pharmasset's Chief Medical Officer. "We are encouraged by the safety profile of RG7128 to date, which, when coupled with the higher barrier to resistance offered by nucleoside and nucleotide analog inhibitors has the potential to improve SVR rates over the
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
(Date:8/29/2014)... -- Research and Markets has announced the ... 2014-2018" report to their offering. ... results in demyelination, axonal transection, and neurodegeneration. The myelin ... the immune system, which targets neurons within the central ... in which the damage of the myelin sheath causes ...
(Date:8/29/2014)... MENLO PARK, Calif. , Aug. 29, 2014 /PR ... ("DelMar" "the Company") today announced the filing of June ... changed its fiscal year end to June 30th in ... stock on a national securities exchange in the timeliest ... with the United States Securities Exchange Commission can be ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... , , Patient Advocacy Partners ... System , NEW YORK and MILAN, ... , the commercial drug development arm of the National Multiple Sclerosis ... the leader in research leading to a cure for type 1 diabetes ...
... , VENLO, The Netherlands ... than 90,000 Italian women published by the Lancet Oncology found ... significantly more effective in preventing invasive cervical cancer than cytology (Pap testing) ... as the digene® HC2 HPV DNA Test), which detects the ...
Cached Medicine Technology:Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 2Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 3Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 4Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 5Study Demonstrates Value of HPV Screening to Prevent Invasive Cervical Cancer 2Study Demonstrates Value of HPV Screening to Prevent Invasive Cervical Cancer 3Study Demonstrates Value of HPV Screening to Prevent Invasive Cervical Cancer 4Study Demonstrates Value of HPV Screening to Prevent Invasive Cervical Cancer 5Study Demonstrates Value of HPV Screening to Prevent Invasive Cervical Cancer 6
(Date:8/30/2014)... WA (PRWEB) August 30, 2014 “In 2013, ... alone,” The Jones Firm says in a recently released article ... “A person was injured in an auto accident every 12 ... 16 minutes,” they continue. “Based on the 2013 statistics, between ... a vehicle collision.” , The threat of an auto accident ...
(Date:8/30/2014)... 30, 2014 Final Cut Pro ... the TransGhost plugin from Pixel Film Studios. , “The ... the ability to tell their scary story in a ... Studios. “Users will make their audience scream with this ... With TransGhost users can awaken evil spirits with over ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 As 500 Zoloft ... defect when give to pregnant mothers, Wright & Schulte LLC ... Cynthia M. Rufe. The remand in the Zoloft ... of 18 states and are involved in one SSRI ... to have their Zoloft birth defect lawsuit sent back to ...
(Date:8/30/2014)... Zensah®, the leader in compression technology and comfort, has created ... sleeves are the first released as part of Zensah’s® DeZign ... classic colors like army green and bold new hues like ... syndrome, shin splints cause dull aches and pains in the ... stress fractures, or over pronation may also be one of ...
(Date:8/30/2014)... TN (PRWEB) August 30, 2014 The ... including nine mobilizations and six muscle energy techniques. Michael ... narrates and demonstrates twenty-seven examination techniques for the SI ... supports Dr. Reiman's live course presentation with North ... Applying a differential diagnosis approach ...
Breaking Medicine News(10 mins):Health News:Startling Washington Auto Accident Statistics Discussed In Recently Released Article By The Jones Firm 2Health News:Pixel Film Studios Released TransGhost Plugin for Final Cut Pro X Today 2Health News:Pixel Film Studios Released TransGhost Plugin for Final Cut Pro X Today 3Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 2Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 3Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 4Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 5Health News:Camo Compression Leg Sleeves Provide Shin Splint Relief for Runners 2Health News:North American Seminars Online PT Continuing Education Course, Examination and Treatment of the SI Joint, Receives Continuing Education Approval in NJ, CA, IL, PA, & TX 2
... ... range of legal needs. , ... New Brunswick, N.J. (Lexis Nexis) January 13, 2010 -- In an effort to provide New ... help them navigate the state,s court system, the Law Offices of Shamy & Shamy ...
... SALEM, N.H. , Jan. 12 Medical and ... emergency hotline for the family and friends of travelers visiting ... striking the area 15 kilometers (10 miles) west of the capital ... members or friends traveling or living in the region should call ...
... Jan. 12 Miami resident Ingrid Mazorra ... to participating in a conspiracy to defraud the Medicare program, announced Assistant ... Attorney Terrence I. Berg of the Eastern District of ... Detroit Field Office; and Daniel R. Levinson , Inspector General of ...
... small amount of amyloid plaques affected olfactory sense, , TUESDAY, ... that loss of smell could serve as an early indicator ... to suffer from loss of smell. But the new research ... the bits of gunk in the brain that cause Alzheimer,s ...
... WASHINGTON , Jan. 12 The U.S. Agency ... Jeff Borns as mission director to South Africa . ... event and administered the oath to Borns. , (Logo:   http://www.newscom.com/cgi-bin/prnh/20091022/USAIDLOGO ... Borns will oversee a program exceeding $500 million this ...
... , ATLANTA , Jan. 12 ... tapped its national animal rescue network to provide financial and logistical ... was destroyed by fire yesterday. The caregiver for the dogs, ... Door Rescuer" and nationally recognized for her passionate efforts to caring ...
Cached Medicine News:Health News:Shamy & Shamy Launches New Web Site Providing Simple Access to Free Online Resources for New Jersey Court System 2Health News:On Call International Opens Haiti Earthquake Emergency Hotline 2Health News:Clinic Manager Pleads Guilty in Medicare Fraud Scheme 2Health News:Clinic Manager Pleads Guilty in Medicare Fraud Scheme 3Health News:New USAID Mission Director for South Africa Sworn In 2Health News:American Dog Rescue Provides Aid to Displaced Dogs Following House Fire of Atlanta's 'Dog Next Door' Animal Rescuer 2
... offers both high-speed and high-volume versatility ... rotor options, making it ideal for a ... Versatility , High-speed (up to 15,000 ... high-volume (4 x 250mL) swinging bucket rotors ...
Inquire...
... The MicroCentrifuge Two Strip Rotor hold 16 ... mess with). Simply close the polycarbonate lid ... to open. Starts and stops in seconds. ... x g. Only five inches in diameter. ...
... Minifuge has an on/off switch which allows user ... improved safety. New hinge, with stainless steel pin ... work yet durable. Spins 6 microcentrifuge tubes at ... g). 6000rpm/2000 x g. 6 inch x 6 ...
Medicine Products: